Glioblastoma Multiforme (GBM) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Glioblastoma Multiforme (GBM) Clinical Trial Report Overview
A total of 2,375 Glioblastoma Multiforme (GBM) clinical trials were conducted as of February 2024. The GBM clinical trial report provides a comprehensive understanding of the GBM clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East and Africa · South and Central America |
Key Countries | · The US
· China · Germany · France · Canada |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Merck & Co Inc
· F. Hoffmann-La Roche Ltd · Novartis AG · Bristol-Myers Squibb Co · Pfizer Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
GBM Clinical Trials Segmentation by Regions and Countries
North America led the Glioblastoma Multiforme clinical trials landscape with more than 50% of the clinical trials conducted as of February 2024.
The key regions considered for GBM clinical trials analysis are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America.
In the country-wise analysis, the US had the highest number of GBM clinical trials, as of February 2024. Canada had the highest average patient enrollment of GBM clinical trials, during the same time.
G7 countries: Among the G7 (the United States, the United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the US had the highest proportion of GBM to oncology clinical trials as of February 2024.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, India held the highest proportion of GBM to oncology clinical trials as of February 2024.
GBM Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the GBM Clinical Trials
Download a Free Sample Report
GBM Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Glioblastoma Multiforme clinical trials are company, institution, and the government. As of February 2024, more than 50% of GBM clinical trials conducted were sponsored by institution sponsor type, followed by the company.
GBM Clinical Trials Analysis by Sponsor Type, 2024 (%)
Buy the Full Report for More Insights into the GBM Clinical Trials Sponsor Types
GBM Clinical Trials - Competitive Landscape
In 2024, Merck & Co Inc conducted the highest number of Glioblastoma Multiforme clinical trials.
A few of the leading sponsors for GBM clinical trials are:
- Merck & Co Inc
- Hoffmann-La Roche Ltd
- Novartis AG
- Bristol-Myers Squibb Co
- Pfizer Inc
GBM Clinical Trials Analysis by Leading Companies, 2024 (%)
Buy the Full Report to Know More About the Leading Players of GBM Clinical Trials
Segments Covered in the Report
GBM Clinical Trials Regional Outlook (2024)
- Asia-Pacific
- Europe
- North America
- Middle East and Africa
- South and Central America
GBM Clinical Trials Country Outlook (2024)
- The US
- China
- Germany
- France
- Canada
GBM Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key investment strategies.
- Helps in identifying time-saving and cost-efficient locations to conduct clinical trials.
- Provides top-level analysis of the global clinical trials market to help in identifying key business opportunities.
- Helps in understanding trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
F. Hoffmann-La Roche Ltd
Novartis AG
Bristol-Myers Squibb Co
Pfizer Inc
AstraZeneca Plc
NovoCure Ltd
Eli Lilly and Co
Bayer AG
C. H. Boehringer Sohn AG & Co KG
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of GBM clinical trials in February 2024?
North America accounted for the highest number of GBM clinical trials as of February 2024.
-
Which country conducted the highest number of GBM clinical trials in February 2024?
The US conducted the highest number of GBM clinical trials as of February 2024.
-
Which sponsor type was the most prominent in the GBM clinical trials in February 2024?
As of February 2024, most of the GBM clinical trials conducted were sponsored by institution sponsor type.
-
Which are the leading sponsors of GBM clinical trials?
A few of the leading sponsors of GBM clinical trials are Merck & Co Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Co, and Pfizer Inc, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.